High-Risk of Metabolic Syndrome after Delivery in Pregnancies Complicated by Gestational Diabetes

Yun Shen,Weiqin Li,Junhong Leng,Shuang Zhang,Huikun Liu,Wei Li,Leishen Wang,Huiguang Tian,Jinbo Chen,Lu Qi,Xilin Yang,Zhijie Yu,Jaakko Tuomilehto,Gang Hu
DOI: https://doi.org/10.1016/j.diabres.2019.03.030
IF: 8.18
2019-01-01
Diabetes Research and Clinical Practice
Abstract:The objective of this study was to investigate the risk of postpartum metabolic syndrome in women with GDM compared with those without GDM in a Chinese population. Tianjin GDM observational study included 1263 women with a history of GDM and 705 women without GDM. Multivariate logistic regression was used to assess risks of postpartum metabolic syndrome between women with and without GDM. Postpartum metabolic syndrome was diagnosed by two commonly used criteria. During a mean 3.53 years of follow-up, 256 cases of metabolic syndrome were identified by using the NCEP ATPIII criteria and 244 cases by using the IDF criteria. Multivariable-adjusted odds ratios of metabolic syndrome in women with GDM compared with those without GDM were 3.66 (95% confidence interval [CI] 2.02-6.63) for NCEP ATPIII criteria and 3.90 (95% CI 2.13-7.14) for IDF criteria. Women with GDM had higher multivariable-adjusted odds ratios of central obesity, hypertriglyceridemia, and high blood pressure than women without GDM. The multivariable-adjusted odds ratios of low HDL cholesterol and hyperglycemia were not significant between women with and without GDM, however, the multivariable-adjusted odds ratio of hyperglycemia became significant when we used the modified criteria. The present study indicated that women with prior GDM had significantly higher risks for postpartum metabolic syndrome, as well as its individual components. Disclosure G. Hu: None. W. Li: None. J. Leng: None. Y. Shen: None. S. Zhang: None. H. Liu: None. W. Li: None. L. Wang: None. H. Tian: None. J. Chen: None. L. Qi: None. X. Yang: None. Z. Yu: None. J. Tuomilehto: Advisory Panel; Self; Novo Nordisk A/S. Board Member; Self; AstraZeneca. Research Support; Self; Bayer AG. Funding European Foundation for the Study of Diabetes; Chinese Diabetes Society; Lilly Program for Collaborative Diabetes Research between China and Europe; Tianjin Women’s and Children’s Health Center; Tianjin Public Health Bureau; National Institute of Diabetes and Digestive and Kidney Diseases (R01DK100790 to G.H.); National Institute of General Medical Sciences (U54GM104940 to G.H.)
What problem does this paper attempt to address?